• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

7.000 -0.370 (-5.02%)
Streaming Delayed Price Updated: 12:27 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cadrenal Therapeutics, Inc. - Common Stock

News headline image
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
December 30, 2025
Via ACCESS Newswire
News headline image
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
December 29, 2025
Via ACCESS Newswire
News headline image
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
December 12, 2025
Via ACCESS Newswire
News headline image
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
December 12, 2025
Via ACCESS Newswire
News headline image
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
August 05, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
June 12, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
June 04, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
May 15, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
May 13, 2025
Via Get News
Topics Death Economy
News headline image
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
April 03, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
March 13, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
March 04, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
February 06, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
February 05, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 09, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
December 31, 2024
From Cadrenal Therapeutics
Via Business Wire
News headline image
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
December 18, 2024
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Sidoti Events, LLC's Virtual August Micro-Cap Conference
August 13, 2024
Via ACCESSWIRE
Cadrenal Therapeutics Inc. (NASDAQ: CVKD) Featured in Coverage of NobleCon19
December 05, 2023
Via Investor Brand Network
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap